NKGen Biotech, Inc. Common Stock (NKGN) Earnings History
Net Loss4 years of earnings data (2021–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
NKGen Biotech, Inc. Common Stock (NKGN) Earnings Overview
As of June 22, 2026, NKGen Biotech, Inc. Common Stock (NKGN) reported trailing twelve-month net income of -$24M, reflecting +71.4% year-over-year growth. The company earned $-0.82 per diluted share over the past four quarters.
Looking at the long-term picture, NKGN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$23M in fiscal 2021.
NKGen Biotech, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), NKTX (-$100M net income), CELC (-$193M net income), NKGN has comparable earnings metrics. Compare NKGN vs FATE →
NKGN Earnings vs Peers
Earnings metrics vs comparable public companies
NKGN Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$44M | +46.6% | -$27M | $-1.54 | - | - |
| 2023 | -$83M | -210.1% | -$30M | $-5.38 | - | - |
| 2022 | -$27M | -15.0% | -$24M | $-1.25 | -34745.5% | -31618.2% |
| 2021 | -$23M | - | -$22M | $-1.08 | -5461.3% | -5131.7% |
Download Data
Export NKGN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NKGN — Frequently Asked Questions
Quick answers to the most common questions about buying NKGN stock.
What is NKGN earnings per share (EPS)?
NKGN trailing twelve-month (TTM) diluted EPS is $-0.82, reflecting +71.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2024 is available in the table on this page.
What is NKGen Biotech, Inc. Common Stock's net income?
NKGen Biotech, Inc. Common Stock (NKGN) trailing twelve-month net income is $-24M as of 2024. Earnings grew +71.4% year-over-year.
Is NKGN profitable?
NKGN is not currently profitable on a TTM basis, reporting a net loss of $-24M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NKGN's earnings growth rate?
NKGN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2024.
What are NKGN's profit margins?
NKGen Biotech, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is NKGN growing earnings?
Yes, NKGN earnings are accelerating — EPS growth of +71.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-24M. Earnings momentum is strengthening.
What was NKGN's best earnings year?
NKGen Biotech, Inc. Common Stock's highest annual net income on record is $-23M, achieved in fiscal year 2021. Earnings history on this page spans 2021 to 2024 and includes all annual and quarterly figures.
What were NKGN's earnings last quarter?
NKGN's most recent reported quarter was Q1 2025. Net income was $15M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.